← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $612B	1,793	+1,793	–	$162B
2	2 Pfizer PFE $166B	1,627	+1,627	–	$139B
3	3 Merck MRK $364B	1,459	+1,459	–	$102B
4	4 AbbVie ABBV $501B	1,287	+1,287	–	$44.6B
5	5 Bristol-Myers Squibb BMY $121B	1,179	+1,179	–	$50.3B
6	6 Amgen AMGN $230B	1,032	+1,032	–	$59.9B
7	7 Gilead Sciences GILD $190B	948	+948	–	$81.1B
8	8 Novartis NVS $279B	763	+763	–	$17B
9	9 GSK GSK $95.9B	639	+639	–	$13.8B
10	10 Regeneron Pharmaceuticals REGN $80.1B	371	+371	–	$17B
11	11 AstraZeneca AZN $251B	331	+331	–	$5.85B
12	12 Myriad Genetics MYGN $397M	261	+261	–	$2.18B
13	13 Jazz Pharmaceuticals JAZZ $13.6B	234	+234	–	$3.42B
14	SGEN 14 DELISTED Seagen Inc. Common Stock SGEN	194	+194	–	$3.96B
15	15 Incyte INCY $22.6B	182	+182	–	$3.35B
16	16 Opko Health OPK $1.02B	131	+131	–	$328M
17	17 DELISTED Immunogen Inc IMGN	128	+128	–	$1.2B
18	SPPI 18 DELISTED Spectrum Pharmaceuticals Inc SPPI	122	+122	–	$321M
19	19 DELISTED Exact Sciences EXAS	121	+121	–	$824M
20	20 Exelixis EXEL $15.1B	121	+121	–	$702M
21	INFI 21 DELISTED Infinity Pharmaceuticals, Inc. INFI	119	+119	–	$762M
22	22 Halozyme HALO $13.3B	110	+110	–	$603M
23	CLVS 23 DELISTED Clovis Oncology, Inc. CLVS	109	+109	–	$1.44B
24	24 Rigel Pharmaceuticals RIGL $875M	94	+94	–	$287M
25	25 Geron GERN $765M	93	+93	–	$63.5M